From Health Affairs and the Robert Wood Johnson Foundation:
Specialty pharmaceuticals–drugs and biologics used to treat chronic, serious, or life-threatening diseases–are complex to manufacture and distribute, often difficult to administer, and may require special patient monitoring. They are a rapidly growing share of the costs borne by both public and private health plans. A patient could pay a few thousand dollars a month to use them, and the annual total cost for some products could exceed $100,000. This policy brief discusses the potential impact of specialty pharmaceuticals on consumers and the health care industry and some of the key challenges for policy makers.
To learn more, click here.